In this research, we clearly confirmed that the expression of HYAL2 is abnormally increased in glioma samples in the TCGA, CGGA databases and glioma specimens, and that the HYAL2 expression level is significantly negatively correlated with the glioma patient’s survival time. Here, HYAL2 is linked to central nervous system cancer.